Role of biological markers and CT severity score in predicting mortality in patients with COVID‑19: An observational retrospective study

  • Authors:
    • Samuel-Bogdan Todor
    • Victoria Bîrluțiu
    • Diana Topîrcean
    • Romeo-Gabriel Mihăilă
  • View Affiliations

  • Published online on: September 28, 2022     https://doi.org/10.3892/etm.2022.11634
  • Article Number: 698
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

COVID‑19 pandemic is a continuing ongoing emergency of public concern. Early identification of markers associated with disease severity and mortality can lead to a prompter therapeutic approach. The present study conducted a multivariate analysis of different markers associated with mortality in order to establish their predictive role. Confirmed cases of 697 patients were examined. Demographic data, clinical symptoms and comorbidities were evaluated. Laboratory and imaging severity scores were reviewed. A total of 133 (19.1%) out of 697 patients succumbed during hospitalization. Obesity was the most common comorbidity, followed by hypertension, diabetes, coronary heart disease and chronic kidney disease. Compared with the survivor patients, non‑survivors had a higher prevalence of diabetes, chronic kidney disease and coronary heart disease, as well as higher values of laboratory markers such as neutrophil‑lymphocyte ratio (NLR), D‑dimer, procalcitonin, IL‑6 and C Reactive protein (CRP) and respectively high values of imaging severity scores. Multivariate regression analysis showed that high values of the proposed markers and chest computerized tomography (CT) severity imaging score were predictive for in hospital death: NLR [hazard ratio (HR): 3.127 confidence interval (CI) 95: 2.137‑4.576]; D‑dimer [HR: 6.223 (CI 95:3.809‑10.167)]; procalcitonin [HR: 4.414 (CI 95:2.804‑6.948)]; IL‑6 [HR: 3.344 (CI 95:1.423‑7.855)]; CRP [HR:2.997 (CI 95:1.940‑4.630)]; and CT severity score [HR: 3.068 (CI 95:1.777‑5.299)]. Laboratory markers and imaging severity scores could be used to stratify mortality risk in COVID‑19 patients.
View References

Related Articles

Journal Cover

November-2022
Volume 24 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Todor S, Bîrluțiu V, Topîrcean D and Mihăilă R: Role of biological markers and CT severity score in predicting mortality in patients with COVID‑19: An observational retrospective study. Exp Ther Med 24: 698, 2022.
APA
Todor, S., Bîrluțiu, V., Topîrcean, D., & Mihăilă, R. (2022). Role of biological markers and CT severity score in predicting mortality in patients with COVID‑19: An observational retrospective study. Experimental and Therapeutic Medicine, 24, 698. https://doi.org/10.3892/etm.2022.11634
MLA
Todor, S., Bîrluțiu, V., Topîrcean, D., Mihăilă, R."Role of biological markers and CT severity score in predicting mortality in patients with COVID‑19: An observational retrospective study". Experimental and Therapeutic Medicine 24.5 (2022): 698.
Chicago
Todor, S., Bîrluțiu, V., Topîrcean, D., Mihăilă, R."Role of biological markers and CT severity score in predicting mortality in patients with COVID‑19: An observational retrospective study". Experimental and Therapeutic Medicine 24, no. 5 (2022): 698. https://doi.org/10.3892/etm.2022.11634